These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36780243)

  • 1. Erratum: Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling.
    Uda A; Eto Y; Li Y; Matsuda H; Demiya S; Watanabe T; Ota M; Iwakiri R; Igarashi A
    Crohns Colitis 360; 2020 Apr; 2(2):otaa036. PubMed ID: 36780243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling.
    Uda A; Eto Y; Li Y; Matsuda H; Demiya S; Watanabe T; Ota M; Iwakiri R; Igarashi A
    Crohns Colitis 360; 2020 Apr; 2(2):otaa017. PubMed ID: 36777303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction to: Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn's Disease: Post Hoc Analyses of VISIBLE Studies.
    Crohns Colitis 360; 2023 Oct; 5(4):otad071. PubMed ID: 38028952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the Optimal Position for Vedolizumab in the Treatment of Ulcerative Colitis: A Simulation Model.
    Scott FI; Shah Y; Lasch K; Luo M; Lewis JD
    Inflamm Bowel Dis; 2018 Jan; 24(2):286-295. PubMed ID: 29361100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erratum:
    Crohns Colitis 360; 2022 Oct; 4(4):otac049. PubMed ID: 36780258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 1, Multiple-Dose Study of Vedolizumab in Japanese Patients With Ulcerative Colitis.
    Kobayashi K; Suzuki Y; Watanabe K; Oda K; Mukae M; Yamada A; Yamagami H; Nishimura A; Okamoto H
    J Clin Pharmacol; 2019 Feb; 59(2):271-279. PubMed ID: 30192378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis.
    Scott FI; Luo M; Shah Y; Lasch K; Vajravelu RK; Mamtani R; Fennimore B; Gerich ME; Lewis JD
    J Crohns Colitis; 2020 Jun; 14(5):575-587. PubMed ID: 31901085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study.
    Motoya S; Watanabe K; Ogata H; Kanai T; Matsui T; Suzuki Y; Shikamura M; Sugiura K; Oda K; Hori T; Araki T; Watanabe M; Hibi T
    PLoS One; 2019; 14(4):e0215491. PubMed ID: 30973957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Outcomes of Vedolizumab Therapy in Ulcerative Colitis and Crohn's Disease at a Tertiary Referral Center.
    Hoffmann P; Krisam J; Stremmel W; Gauss A
    Dig Dis; 2019; 37(1):33-44. PubMed ID: 30134234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada.
    Fenu E; Lukyanov V; Acs A; Radu X; Stypa S; Fischer A; Marshall JK; Oppe M
    Pharmacoecon Open; 2022 Jul; 6(4):519-537. PubMed ID: 35474178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
    McLean LP; Cross RK
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corrigendum to: Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis.
    Kierkus J; Pesegova M; Klopocka M; Brankovic M; Kasai N; Efuni S; Kong J; Nakajima Y; Jordan C; Matsui T; Feagan BG; Strout V
    Crohns Colitis 360; 2020 Oct; 2(4):otaa092. PubMed ID: 36780244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Guardiola J; Jahnsen J; Lees C; Louis E; Lukáš M; Reinisch W; Roblin X; Jang M; Byun HG; Kim DH; Lee SJ; Atreya R
    BMC Gastroenterol; 2022 Jun; 22(1):291. PubMed ID: 35676620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis.
    Dart RJ; Samaan MA; Powell N; Irving PM
    Clin Exp Gastroenterol; 2017; 10():57-66. PubMed ID: 28424557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience.
    Erdoğan Ç; Yeşil B; Bacaksız F; Arı D; Gökbulut V; Yüksel M; Özderin Özin Y; Kayaçetin E
    Turk J Gastroenterol; 2022 Oct; 33(10):831-837. PubMed ID: 35946879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhagen, Denmark
    Gastroenterol Hepatol (N Y); 2019 May; 15(5 Suppl 2):1-24. PubMed ID: 31632213
    [No Abstract]   [Full Text] [Related]  

  • 17. Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY).
    Peyrin-Biroulet L; Loftus EV; Colombel JF; Danese S; Rogers R; Bornstein JD; Chen J; Schreiber S; Sands BE; Lirio RA
    Gastroenterology; 2021 Oct; 161(4):1156-1167.e3. PubMed ID: 34144047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study.
    Atia O; Shavit-Brunschwig Z; Mould DR; Stein R; Matar M; Aloi M; Ledder O; Focht G; Urlep D; Hyams J; Broide E; Weiss B; Levine J; Russell RK; Turner D
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):31-42. PubMed ID: 36306803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pediatric case of moderate active ulcerative colitis successfully treated with vedolizumab in Japan.
    Ikeuchi A; Kakiuchi T; Ibi A; Matsuo M
    Clin J Gastroenterol; 2021 Feb; 14(1):146-151. PubMed ID: 33040281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current position on Vedolizumab for ulcerative colitis and Crohn's disease].
    Schreiber S; Dignass AU; Hartmann H; Kruis W; Rogler G; Siegmund B; Stallmach A; Witte C; Bokemeyer B
    Z Gastroenterol; 2015 Jun; 53(6):591-602. PubMed ID: 26016456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.